Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D R Budman

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
The New England Journal of Medicine|May 5, 1994
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinomaW C Wood, D R Budman, A H Korzun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemiaC A Puccio, A Mittelman, S M Lichtman, et al.
The Journal of Experimental Medicine|January 1, 1989
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemiaZ M Sthoeger, M Wakai, D B Tse, et al.
Medical and Pediatric Oncology|January 1, 1994
Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphomaH Ozer, J R Anderson, B A Peterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancerD A Berry, H B Muss, A D Thor, et al.
Seminars in Oncology|June 1, 1987
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group BR J Mayer, C A Schiffer, B A Peterson, et al.
Seminars in Oncology|June 1, 1985
Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I studyR J Mayer, C A Schiffer, B A Peterson, et al.
Journal of the National Cancer Institute|September 25, 1998
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancerA D Thor, D A Berry, D R Budman, et al.
Journal of the National Cancer Institute|August 27, 1998
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group BD R Budman, D A Berry, C T Cirrincione, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancerF A Holmes, S E Jones, J O'Shaughnessy, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
The New England Journal of Medicine|May 5, 1994
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinomaW C Wood, D R Budman, A H Korzun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemiaC A Puccio, A Mittelman, S M Lichtman, et al.
The Journal of Experimental Medicine|January 1, 1989
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemiaZ M Sthoeger, M Wakai, D B Tse, et al.
Medical and Pediatric Oncology|January 1, 1994
Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphomaH Ozer, J R Anderson, B A Peterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancerD A Berry, H B Muss, A D Thor, et al.
Seminars in Oncology|June 1, 1987
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group BR J Mayer, C A Schiffer, B A Peterson, et al.
Seminars in Oncology|June 1, 1985
Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I studyR J Mayer, C A Schiffer, B A Peterson, et al.
Journal of the National Cancer Institute|September 25, 1998
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancerA D Thor, D A Berry, D R Budman, et al.
Journal of the National Cancer Institute|August 27, 1998
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group BD R Budman, D A Berry, C T Cirrincione, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancerF A Holmes, S E Jones, J O'Shaughnessy, et al.
Pageof 11